Bluejay Diagnostics
BJDX
7 hedge funds and large institutions have $345K invested in Bluejay Diagnostics in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
75% more funds holding
Funds holding: 4 → 7 (+3)
42% more capital invested
Capital invested by funds: $243K → $345K (+$101K)
18.47% more ownership
Funds ownership: 16.09% → 34.57% (+18%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$131K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$31.7K |
| 3 |
Renaissance Technologies
New York
|
+$15.2K |
| 4 |
VF
Virtu Financial
New York
|
+$9.65K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$9.65K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$2.76K |
| 2 |
JP Morgan Chase
New York
|
-$74 |
BJDX Hedge Fund Activity: Q1 2024 in Review
7 of the 6,959 institutional investors tracked by Wall St. Rank reported a position in Bluejay Diagnostics (BJDX) for Q1 2024, worth a combined $345K — up 42% from $243K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BJDX positions and 0 closed out — a net gain of 3 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, adding an estimated $131K. The largest seller was Citadel Advisors, cutting an estimated $2.76K.
- 7 institutional investors held Bluejay Diagnostics (BJDX) as of Q1 2024, up from 4 in Q4 2023.
- Funds reported $345K of Bluejay Diagnostics stock for Q1 2024, up 42% quarter-over-quarter.
- 3 funds opened new Bluejay Diagnostics positions in Q1 2024 and 0 closed out, a net change of +3 holders.
- The largest Bluejay Diagnostics buyer in Q1 2024 was Armistice Capital, an estimated $131K added.
- The largest Bluejay Diagnostics seller in Q1 2024 was Citadel Advisors, an estimated $2.76K sold.
Based on aggregated 13F filings for Q1 2024.